Jerry W and Carol Lee Levin Professor of Operations Management.
Actually, it depends, first on regulatory approval and then on the size of the trial. For the approval, I would imagine this would also be easier for smaller trials including hundreds of patients (for example, for medical device approvals) as opposed to thousands of patients for broad indication drug trials. The main implementation issue in these cases is the computational capability. The current research is addressing that.